Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/30/2025 07:15 PDT] GERN Expected to Trade Down After Bearish Patterns Develop
• [07/24/2025 07:15 PDT] GERN Expected to Trade Up After Bullish Patterns Develop
• [07/15/2025 12:04 PDT] Geron Corporation (NASDAQ:GERN), Down By 100% ($1.42) From $1.42 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [07/10/2025 07:15 PDT] GERN Expected to Trade Up After Bullish Patterns Develop
• [07/02/2025 08:07 PDT] GERN Expected to Trade Down After Bearish Patterns Develop